Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Aug 08, 2022 10:58am
225 Views
Post# 34878687

RE:Drop and Pop

RE:Drop and PopThey are sitting on something here, and from the looks of how we went from 18-20 to 34 and back to 18, completely wiping out everything related to this deal, tells me that:

1) the trading base (not investing base) took whatever profit off the table they could
2) based upon the short sales covered, they are leveraging the sentiment and historical reputation of the R&F deal to make it sound like the Abbvie deal is "nothing", when in fact it is not. 

Saying this deal is the biggest deal they have ever signed, one needs to tally the total deal from Wanbang including the unrealized portion to compare to. 

Here is another clear statement from the interview:

Congratulation on the AbbVie deal! So, What does this mean for Sirona Biochem?
HV: Our deal with AbbVie is a game-changer for Sirona Biochem. It is the biggest-ever deal we have signed to date. It took us over a decade to perfect our technology platform, and this deal validates all our hard work. Having AbbVie as a partner places us in the big leagues, and we are in line for considerable revenue flow for years to come. I see great potential in collaborating with AbbVie in developing future products. This is only the beginning of our vision for Sirona.

<< Previous
Bullboard Posts
Next >>